Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Immunoglobulin Light-Chain Amyloidosis
About this trial
This is an interventional treatment trial for Immunoglobulin Light-Chain Amyloidosis focused on measuring AL Amyloidosis, Bortezomib, cyclophosphamide, thalidomide, randomized controlled trial, prognosis, Side effect
Eligibility Criteria
Inclusion Criteria:
1.Signed the written informed consent; 2.18 years old ≤ age ≤ 80 years old, no restriction on gender; 3.AL amyloidosis was confirmed by pathological biopsy in the accumulated system or organ (kidney, heart, liver, skin), and excluded other secondary factors; 4.The proliferation of monoclonal plasma cells was confirmed by fixed electrophoresis of bone marrow or blood/urine.
Exclusion Criteria:
- Pathological biopsy showed non-AL amyloidosis;
- Abnormal proliferation of plasma cells reached the standard of multiple myeloma;
- Other hematological system tumors;
- Cushing's syndrome;
- Active hepatitis;
5.Pregnant or lactating women;
Sites / Locations
- Guangdong Provincial People'S HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group1
Group2
Group1 is the AL amyloidosis patients who have bortezomib-thalidomide-dexamethason-based regimens for their treatment.
Group2 is the AL amyloidosis patients who have bortezomib-cyclophosphamide-dexamethason-based regimens for their treatment.